Medivir AB: Late stage broad pipeline: remetinostat, Ph 3 ready topical HDAC inhibitor for early-stage cutaneous T-cell lymphoma; MIV-711, cathepsin K inhibitor for OA, Ph 2 data showed disease modifying effect on knee structure; birinipant, bivalent SMAC mimetic read out positive Ph 1/2 combo (keytruda) data Oct 18: confirmed PR, good safety.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase III
Disease Space
Anti-inflammatory, Oncology
Industry
Biotechnology
Listing
Public
Market Cap
<100MM
Website:
Address:
Lunastigen 7
Huddinge, SE-141 22
Sweden

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.